Esperion Therapeutics Inc (ESPR)
2.445
-0.08
(-2.98%)
USD |
NASDAQ |
Nov 12, 14:42
Esperion Therapeutics Revenue (Annual): 116.33M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 116.33M |
| December 31, 2022 | 75.48M |
| December 31, 2021 | 78.45M |
| December 31, 2020 | 227.55M |
| December 31, 2019 | 148.36M |
| December 31, 2018 | |
| December 31, 2017 | |
| December 31, 2016 | |
| December 31, 2015 |
| Date | Value |
|---|---|
| December 31, 2014 | |
| December 31, 2013 | |
| December 31, 2012 | |
| December 31, 2011 | |
| December 31, 2002 | |
| December 31, 2001 | |
| December 31, 2000 | 0.002M |
| December 31, 1999 | 0.001M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
75.48M
Minimum
2022
227.55M
Maximum
2020
129.23M
Average
116.33M
Median
2023
Revenue (Annual) Benchmarks
| Perspective Therapeutics Inc | -- |
| Nektar Therapeutics | 90.12M |
| Alaunos Therapeutics Inc | 0.005M |
| Oragenics Inc | -- |
| Cocrystal Pharma Inc | -- |